Prothena Corp. (PRTA) Tops Q3 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. SPY
3. CRWV
4. BAC
5. RKLB
6. BLK
7. CAT
8. FMC
9. RXRX
10. NOW

Go back to Prothena Corp. (PRTA) Tops Q3 EPS by 8c

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

November 12, 2024 4:05 PM EST

Net cash used in operating and investing activities was $45.2 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million PRX012, a potential single-injection once-monthly subcutaneous treatment, is designed to address the unmet need of millions of patients with presymptomatic or early symptomatic Alzheimer's disease; Prothena expects to report multiple clinical readouts starting in mid-2025 and continuing throughout the year from the ongoing Phase 1 ASCENT clinical trials Results from partner Roche evaluating prasinezumab in patients with early Parkinsons disease from the Phase 2... More